IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024

• Preclinical data supports potential for proprietary nsCAR platform to selectively eliminate cancer cells while preserving healthy tissue - Gamma-delta nsCAR platform emerging as an advanced technology for targeting hematologic and solid tumor cancers NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ:INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced new preclinical data from its non-signaling gamma-delta T cell based Chime ...